Tilray Medical will showcase its expertise at Cannabis Europa London 2026 on May 26 with a panel titled “Evidence First: Designing Public Policy Through Data and Trials” at The Barbican. It co-hosts the afterparty and leverages operations in 20 regulated markets to advance patient access in Europe.
Tilray Medical, a global leader in medical cannabis research and distribution, is participating in Cannabis Europa London 2026 on May 26 at The Barbican. The company aims to engage policymakers, healthcare professionals, and industry leaders to discuss regulation, innovation and patient access frameworks in Europe.
José Tempero, Director of International Medical Affairs, will present on the “Evidence First: Designing Public Policy Through Data and Trials” panel at 12:00 p.m., exploring how pilot programmes, clinical research and real-world data inform responsible cannabis policy across Europe.
Tilray Medical will co-host the event afterparty with Lyphe Clinic, its U.K. medical cannabis platform, while highlighting its operations in over 20 regulated markets and its portfolio of brands to support scalable patient access and pharmaceutical-grade standards.
